Product Description
HBS-102 is a Melanin Concentrating Hormone Receptor 1 (MCHR1) antagonist that has the potential to offer a novel approach to the treatment of narcolepsy including the symptoms of Rapid Eye Movement (REM) sleep dysregulation, such as cataplexy, hallucinations and sleep paralysis. Sleep abnormalities, including narcolepsy and cataplexy, are a common feature of Prader-Willi syndrome. (Sourced from: https://www.pwsausa.org/harmony-biosciences-acquires-asset-with-novel-mechanism-of-action-for-the-potential-treatment-of-narcolepsy-and-other-rare-neurological-diseases/)
Mechanisms of Action: MCHR Antagonist
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Harmony Biosciences, LLC
Company Location: PLYMOUTH MEETING PA 19462
Company CEO: John C. Jacobs
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
- Clinical Outcomes Reported - Harmony Biosciences, LLC announced they will present P0 Prader-Willi Syndrome results in 1H24 for CSTI-100
Highest Development Phases
Phase 0: Prader-Willi Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/24/2024 |
News Article |
ConSynance Therapeutics Announces U.S. FDA Grants Rare Pediatric Disease Designation to CSTI-500, a Potential First-in-Class Therapy for Prader-Willi Syndrome |